Ryvu TherapeuticsS.A.
Research and experimental development in natural sciences and engineering
Overview
RYVU Therapeutics is a clinical-stage biopharmaceutical company developing novel small-molecule therapies for precision oncology. Its pipeline includes RVU305 for MTAP-deleted tumors, romaciclib (RVU120) for R/R AML, myelofibrosis and LR-MDS, and dapolsertib for DLBCL. The company runs clinical studies and advances programs in kinase, synthetic lethality, and immuno-oncology pathways.
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 17.10
- High
- PLN 17.18
- Low
- PLN 16.60
- Volume
- 17.89K
- Avg. vol.
- 13.72K
- Market cap
- PLN 390.73M
- P/E ratio
- –
- EPS
- -PLN 2.94
- Shares outstanding
- 23.12M
- 52-week
- PLN 15.44 – 17.50
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLSELVT00013
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 3.24m | USD -4.52m | USD -3.53m |
| Q1 2026 | USD 4.58m | USD -3.35m | USD -3.42m |
| Q4 2025 | USD 4.52m | USD -4.22m | USD -4.42m |
| Q3 2025 | USD 3.75m | USD -6.38m | USD -6.20m |
Results for Q3 2026:Nov 19, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2007-08-10. Active
40 1280 0003 0000 0031 8529 5031- 62 1280 0003 0000 0031 8529 5023
97 1240 4588 1111 0000 5485 1786
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jun 13, 2011 | Shareholders' meeting convened |
Public aid
53 public aid cases recorded, with a total value of $86,209,007.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 10, 2026 | Aid for research and development projects: industrial research | $3.1M$3,064,666 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Mar 10, 2026 | Aid for research and development projects: experimental development | $2.3M$2,326,177 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Apr 22, 2025 | Aid for research and development projects: industrial research | $2.5M$2,480,957 | Prezes Agencji Badań Medycznych |
European Funds
4 projects recorded: 3 from FE lists ($14,123,711) and 1 Commission grant (FTS) ($0).
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-10-01 | PERO – Predictive Engineering for Rational Oncology: funkcjonalne mapowanie celów terapeutycznych w onkologii. | $5.0M$5,011,779 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2023-05-01 | ONCO Prime: nowe możliwości personalizowanej terapii przeciwnowotworowej w oparciu o hodowlę komórek pierwotnych od pacjenta, charakteryzację omiczną i testy funkcjonalne. | $6.3M$6,268,132 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2018-12-02 | Nowa terapia celowana nowotworów z delecją genu MTAP – II faza. | $2.8M$2,843,801 | Fundusze Europejskie dla Nowoczesnej Gospodarki |
Tenders
2 tenders recorded as contractor, with a total value of $3,202.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Nov 20, 2024 | Konsultacje sylabusa w celu modyf. kierun: Biologia I i II st. oraz Zarządzanie Zasob. Przyrody II st. -Key to the future-Kompleksowy program rozwoju kształcenia na potrzeby branż kluczowych UJ-22 cz. | $3,017$3,017 | Uniwersytet Jagielloński | |
| Oct 29, 2024 | Konsultacje sylabusa w celu modyf. kierun: Biologia I i II st. oraz Zarządzanie Zasob. Przyrody II st. -Key to the future-Kompleksowy program rozwoju kształcenia na potrzeby branż kluczowych UJ-22 cz. | $185$185 | Uniwersytet Jagielloński |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | Waste generation | Active |
Authorized Representatives
Manner of representation
In the case of a multi-member management board, two members of the management board acting jointly, or a member of the management board acting jointly with one of the joint commercial proxies, are authorized to represent the company.
Supervisory board
Beneficial owners
No beneficial owners recorded for the company Ryvu Therapeutics.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Medrisesp. z o.o. | $571,656.57 | medrise.pl | ||
| Green ZebrasS.A. | $328,658.91 | whygreenzebras.pl | ||
| Explorna Therapeuticssp. z o.o. | $304,662.00 | explorna.com | ||
| Biostat Research And Developmentsp. z o.o. | $50,225.77 | biostat.com.pl | ||
| NanovelosS.A. | $24,842.03 | nanovelos.com | ||
| 4cell TherapiesS.A. | $9,123.06 | 4celltherapies.com | ||
| Oncotherics PolandS.A. | $7,565.33 | oncotherics.com | ||
| NanotheaS.A. | $115.78 | nanothea.com | ||
| MolecureS.A. | $10.77 | molecure.com | ||
| Meritrosp. z o.o. | $0.05 | meritro.com |
Change history
| Date | Event | |
|---|---|---|
| 2023-01-17 | Share capital change (7,342,189.60 PLN → 9,248,059.20 PLN) | |
| 2020-10-09 | Address change (Bobrzyńskiego 14, 30-348, Kraków → Ul. Leona Henryka Sternbacha 2, 30-394, Kraków) | |
| 2020-08-18 | Share capital change (6,388,491.60 PLN → 7,342,189.60 PLN) | |
| 2019-10-01 | Name change (Selvita → Ryvu Therapeutics) | |
| 2018-03-16 | Share capital change (5,508,491.60 PLN → 6,388,491.60 PLN) |
FAQ
Last updated: 2026-10-07